US 12,433,838 B2
Liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapy
Charles Dumontet, Venissieux (FR); and Abdelkamel Chettab, Lyons (FR)
Assigned to Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); Université Claude Bernard Lyon 1, Villeurbanne (FR); Hospices Civils de Lyon, Lyons (FR); and Centre Léon Bérard, Lyons (FR)
Appl. No. 16/760,215
Filed by Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); Université Claude Bernard Lyon 1, Villeurbanne (FR); Hospices Civils de Lyon, Lyons (FR); and Centre Léon Bérard, Lyons (FR)
PCT Filed Oct. 30, 2018, PCT No. PCT/FR2018/052695
§ 371(c)(1), (2) Date Apr. 29, 2020,
PCT Pub. No. WO2019/086806, PCT Pub. Date May 9, 2019.
Claims priority of application No. 1760209 (FR), filed on Oct. 30, 2017.
Prior Publication US 2021/0177755 A1, Jun. 17, 2021
Int. Cl. A61K 31/739 (2006.01); A61K 9/127 (2006.01); A61K 31/7048 (2006.01); A61K 45/06 (2006.01); A61K 47/36 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 31/7048 (2013.01); A61K 45/06 (2013.01); A61K 47/36 (2013.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 2317/24 (2013.01)] 15 Claims
 
1. A pharmaceutical combination product for a human comprising:
a liposomal formulation consisting of one or more liposomes each encapsulating only a bacterial lipopolysaccharide (LPS) as a single active ingredient and containing no antigen; and
at least one cytotoxic compound chosen from the group consisting of:
the therapeutic antibody rituximab,
a chemotherapeutic agent chosen from the group consisting of:
etoposide and doxorubicin.